Neural Regeneration Research (SCI-E Indexed, 2017 IF: 1.769) is a peer-reviewed open-accessed journal published with monthly. NRR aims to duly report the prospective, creative, and popular basic and clinical research in the international field of neuroregeneration. NRR focuses on rapidly publishing the articles pertaining to brain injury, spinal cord injury, peripheral nerve injury, neurodegenerative diseases, and neuroimaging, which reflect the latest progress in neuroregeneration research, and aims to highlight the unique scientific characteristics of each article. Journal Website: www.nrronline.org.
Clinical Trials in Degenerative Diseases (CTDD) is an open access, peer-reviewed, online journal with Quarterly print on demand compilation of issues published. It covers clinical trials, research, therapeutics and education for all aspects of degenerative disorders. We publish articles on general trial methodology as well as protocols, commentaries and traditional results papers - regardless of outcome or significance of findings.
The Journal aims to experiment with, and refine, innovative approaches to improving standardized reporting of trials. Clinical Trials in Degenerative Diseases promises fair, rigorous peer review, broad scope, and wide readership among peers and societies.
Taking advantage of online publication, we welcome investigators and researchers to provide not only all outcome measures, as well as varying analyses and interpretations, but also in-depth descriptions of what they did and what they learnt. This sharing of direct experience is fundamental to improving the quality and conduct of trials worldwide.
Abstracting and Indexing Information
The journal is registered with the following abstracting partners:
Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing's Electronic Databases, Ex Libris – Primo Central, Google Scholar, Hinari, Infotrieve, National Science Library, Netherlands ISSN centre, ProQuest, TDNet, Wanfang Data
The journal is indexed with, or included in, the following:
Wolters Kluwer and Journal/Association are committed to meeting and upholding standards of ethical behavior at all stages of the publication process. We follow closely the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE) and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices in order to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit www.Medknow.com/EthicalGuidelines.asp
Open Access Publication and Creative Commons Licensing
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Wolters Kluwer Medknow provides for long-term digital preservation through two primary partnerships, Portico and CLOCKSS.
Portico is a leading digital preservation service worldwide. The content is preserved as an archival version and is not publically accessible via Portico, but is provided when required under specific conditions, such as discontinuation of the collection or catastrophic failure of the website.
CLOCKSS will enable any library to maintain their own archive of content from Wolters Kluwer Medknow and other publishers, with minimal technical effort and using cheaply available hardware.
Ahead of Print policy
Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. Wolters Kluwer Medknow has a policy that changes will not be made after publication of an article without following accepted procedures for making corrections to the scientific record.
While advertisements are crucial to this journal to be able to keep all content free for everyone, ethical considerations are in place to ensure the integrity of the journal and its content:
- "Pop-up" and "banner" ads appear on a random, rotating basis. The advertiser has no control or input over the pages where their ads appear.
- The Editorial Board has full and final approval over the content of all advertisements.
- Advertisers will never be shown any manuscripts or other content prior to publication.
The areas of interest for the journal comprise clinical trial protocols and clinical translational papers of degenerative disease. Aiming to expedite the translation of scientific discovery in the field of degenerative disease into new or improved standards of care, it promotes a wide-ranging exchange between basic, preclinical, clinical and epidemiologic outcomes research, including neurodegnerative diseases, cardiovascular diseases, orthopedic degenerative diseases and other related disorders.
The following topics are covered in the journal:
Design, Conduct, Analysis, Statistical methods, Methodologies, Data management methodologies, Synthesis, History, Ethics, Regulation and clinical or policy impact.
Clinical Trials in Degenerative Diseases has emerged as an important forum for the experts from the following disciplines including medicine, biostatistics, epidemiology, computer science, management science, pharmaceutical science, and bioethics.